LeonaBio, Inc. (LONA) - Total Liabilities
Based on the latest financial reports, LeonaBio, Inc. (LONA) has total liabilities worth $22.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LeonaBio, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See LONA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
LeonaBio, Inc. Competitors by Total Liabilities
The table below lists competitors of LeonaBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oil Terminal C
RO:OIL
|
Romania | RON325.29 Million |
|
Emerita Resources Corp
V:EMO
|
Canada | CA$9.19 Million |
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
Korea | ₩136.81 Trillion |
|
G8 Education Ltd
AU:GEM
|
Australia | AU$1.00 Billion |
|
Quality Construction Products Public Company Limited
BK:Q-CON
|
Thailand | ฿397.47 Million |
|
Rangdong Light source and Vacuum flask JSC
VN:RAL
|
Vietnam | ₫4.74 Trillion |
|
Solitario Exploration & Royalty Corp
NYSE MKT:XPL
|
USA | $416.00K |
|
Pathfinder Bancorp Inc
NASDAQ:PBHC
|
USA | $1.30 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down LeonaBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LONA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LeonaBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LeonaBio, Inc. (2018–2025)
The table below shows the annual total liabilities of LeonaBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.36 Million | +361.77% |
| 2024-12-31 | $13.94 Million | -53.63% |
| 2023-12-31 | $30.06 Million | +30.59% |
| 2022-12-31 | $23.02 Million | +110.69% |
| 2021-12-31 | $10.92 Million | +106.85% |
| 2020-12-31 | $5.28 Million | -75.90% |
| 2019-12-31 | $21.91 Million | +10.55% |
| 2018-12-31 | $19.82 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more